Swedish Value-Based Pricing reimbursement system (TLV)
A system used in Sweden to decide if a medicine should be publicly funded based on its health benefits and cost-effectiveness.
At a glance
Use when
Evaluating new medicines for public reimbursement in Sweden
Avoid when
Assessing non-pharmaceutical health technologies or in systems without value-based pricing frameworks
Inputs
Medicine's clinical and economic data, including comparative effectiveness and cost-effectiveness analyses
Outputs
Reimbursement decision with conditions or price recommendations
How it works
The TLV framework, managed by Sweden's Dental and Pharmaceutical Benefits Agency, evaluates pharmaceuticals for reimbursement under the Act on Pharmaceutical Benefits. It assesses whether the requested price is justified by the medicine's health-economic value, integrating clinical benefit, cost-effectiveness, and patient impact.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Assumptions
- Therapeutic benefit can be quantified and compared; cost-effectiveness thresholds reflect societal value
- Strengths
- Transparent, legally grounded process; integrates clinical and economic evidence; promotes equitable access
- Limitations
- May not fully capture innovation or rare disease value; dependent on quality of submitted evidence
- Also known as
- TLV, Swedish TLV, Pharmaceutical Benefits Agency system
Questions this answers
- › How cost-effective is a medicine compared to alternatives?
- › Does the medicine provide significant health benefits to justify its price?
- › What is the impact on patients and the healthcare system?
- › Is the requested price aligned with the medicine's therapeutic value?
- › How does the medicine fit within existing treatment pathways?
- › What are the budget implications for public reimbursement?
References & sources
Similar by meaning
- Swedish severity-based cost-effectiveness threshold framework
- Czech HTA framework for pharmaceutical reimbursement (SUKL cost-effectiveness and budget-impact)
- Norwegian Absolute Shortfall severity operationalization (drug reimbursement)
- Swedish experience-based EQ-5D-3L value sets (Burström)
- Swedish EQ-5D-5L experience-based value sets (Burström TTO & VAS)
Beta record. Based on the original catalogue summary; primary-source enrichment pending.